MITSUBISHI-HEAVY-IND
18.4.2019 09:23:11 CEST | Business Wire | Press release
Premiering for the first time in the world, Mitsubishi Heavy Industries Thermal Systems, Ltd., a Group company of Mitsubishi Heavy Industries, Ltd. (MHI) (TOKYO: 7011), is adopting R454C, a refrigerant with an extremely low global warming potential (GWP), in a 1-horsepower (HP) class residential air-conditioner. The conventional shortcomings of the R454C,for example; inferior heat exchanger performance attributable to it being a mixed refrigerant have been overcome through the use of proprietary technology that optimize the heat exchanger’s flow volume and other measures. The company has already developed a demonstration unit of the residential air-conditioner featuring R454C and preparations are underway towards mass production with an eye on an initial launch into the European market, where environmental regulations are particularly stringent.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190418005241/en/
The R454C refrigerant has an ozone depletion potential (ODP) of 0 (zero) and a GWP of 146 (CO2 =1). The latter value is approximately 1/14th and 1/5th the respective GWP levels of refrigerants currently and most widely used in air-conditioners of small/medium scale: R410A (2090) and R32 (675). The overall global warming impact (GWP x refrigerant volume) from the demonstration unit’s refrigerant represents a 91.3% reduction from the level of MHI Thermal Systems’ previous model for the European market*1 .
Worldwide initiatives aimed at stopping global warming were strengthened in October 2016 with the adoption of the “Kigali Amendment” to the Montreal Protocol on Substances that Deplete the Ozone Layer. Named after the capital city of Rwanda where the delegates met, the Kigali Amendment mandates progressive reduction in hydrofluorocarbons (HFC), substances that do not deplete the ozone but do adversely impact global warming*2 . In addition, since 2015 the member nations of the European Union (EU), where environmental awareness is deeply entrenched, have gradually expanded regulations affecting the sale and usage of substances, including HFCs, that have GWP values of 150 and higher, contributing to global warming. MHI Thermal Systems’ development of the world’s first small-capacity residential air-conditioner adopting the R454C refrigerant is thus a leading and positive response to these international movements.
Going forward, MHI Thermal Systems will continue to dedicate its resources to developing and marketing high-performance products using low-GWP refrigerants, thereby contributing to protection of the global environment in markets everywhere.
|
Notes |
||||
|
*1: |
The top-of-the-line SRK25ZSX-S with a piping length of 5m, which adopts the R410A refrigerant |
|||
|
*2: |
These substances are subject to the terms of both the Montreal Protocol (1987) and the preceding Vienna Convention for the Protection of the Ozone Layer (1985). |
|||
About Mitsubishi Heavy Industries Group
Mitsubishi Heavy Industries, Ltd. (MHI), headquartered in Tokyo, is one
of the world’s leading industrial firms with 80,000 group employees and
annual consolidated revenues of around 38 billion U.S. dollars. For more
than 130 years, the company has channeled big thinking into innovative
and integrated solutions that move the world forward. MHI owns a unique
business portfolio covering land, sea, sky and even space. MHI delivers
innovative and integrated solutions across a wide range of industries
from commercial aviation and transportation to power plants and gas
turbines, and from machinery and infrastructure to integrated defense
and space systems.
For more information, please visit MHI’s
website: www.mhi.com/index.html
For
Technology, Trends and Tangents, visit MHI’s new online media SPECTRA
:
spectra.mhi.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190418005241/en/
Contact:
PRESS CONTACT: Corporate Communication Department Mitsubishi Heavy Industries, Ltd. James Bennett, +81-(0)3-6275-6200 Email: mediacontact_global@mhi.co.jp
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom